These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27155188)

  • 1. Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
    Holland DP; Hamilton CD; Stout JE
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):827-31. PubMed ID: 27155188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
    Dutta NK; Illei PB; Peloquin CA; Pinn ML; Mdluli KE; Nuermberger EL; Grosset JH; Karakousis PC
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3726-31. PubMed ID: 22547623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.
    Dawson R; Narunsky K; Carman D; Gupte N; Whitelaw A; Efron A; Barnes GL; Hoffman J; Chaisson RE; McIlleron H; Dorman SE
    Int J Tuberc Lung Dis; 2015 Jul; 19(7):780-6. PubMed ID: 26056101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
    Carr W; Kurbatova E; Starks A; Goswami N; Allen L; Winston C
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(8):285-289. PubMed ID: 35202353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present status of chemotherapy for tuberculosis.
    Grosset JH
    Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
    Sterling TR; Alwood K; Gachuhi R; Coggin W; Blazes D; Bishai WR; Chaisson RE
    AIDS; 1999 Oct; 13(14):1899-904. PubMed ID: 10513648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
    Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
    Feng Z; Miao Y; Peng Y; Sun F; Zhang Y; Li R; Ge S; Chen X; Song L; Li Y; Wang X; Zhang W
    BMC Infect Dis; 2023 May; 23(1):300. PubMed ID: 37158831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.